Vis enkel innførsel

dc.contributor.authorEl-Salhy, Magdy
dc.contributor.authorMazzawi, Tarek
dc.contributor.authorHausken, Trygve
dc.contributor.authorHatlebakk, Jan Gunnar
dc.date.accessioned2022-08-05T11:07:00Z
dc.date.available2022-08-05T11:07:00Z
dc.date.created2022-04-01T09:46:36Z
dc.date.issued2022
dc.identifier.issn1350-1925
dc.identifier.urihttps://hdl.handle.net/11250/3010354
dc.description.abstractBackground Fecal microbiota transplantation (FMT) interventions have recently been advocated to not succeed in every irritable bowel syndrome (IBS) patient, since the outcome of FMT varies with the IBS subset. This study investigated the factors potentially affecting FMT response using the same patient cohort used in our previous study. Methods This study included 109 patients who received allogenic FMT. Patients completed five questionnaires that assessed their symptoms and quality of life at baseline and at 2 weeks, 1 month, and 3 months after FMT. Patients also provided fecal samples at baseline and 1 month after FMT. The fecal bacterial profile and dysbiosis index (DI) were determined using 16S rRNA gene PCR DNA amplification covering variable genes V3–V9. Response to FMT was defined as a decrease of ≥50 points in the total IBS-SSS score after FMT. Results An IBS patient's response or nonresponse to FMT was not determined by age, IBS duration, IBS subtype, IBS symptoms, fatigue, quality of life, or DI. There were more male nonresponders than responders, and the fluorescence signals of Alistipes were lower in nonresponders than in responders. Conclusions We concluded that IBS patients who are male and/or have low fecal Alistipes levels are most likely to not respond to FMT treatment. Whether low fecal Alistipes levels could be used as a marker for predicting the outcome of FMT remains to be determined.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIrritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantationen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumbere14353en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1111/nmo.14353
dc.identifier.cristin2014443
dc.source.journalNeurogastroenterology and Motilityen_US
dc.identifier.citationNeurogastroenterology and Motility. 2022.en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal